← 返回

BRAF D594A 突变在结直肠癌中定义了一个与功能性 CD8(+) T 细胞浸润相关的独特生物学和免疫调节亚组

英文原题:BRAF D594A mutation defines a unique biological and immuno-modulatory subgroup associated with functional CD8(+) T cell infiltration in colorectal cancer.

查看英文原题

BRAF D594A mutation defines a unique biological and immuno-modulatory subgroup associated with functional CD8(+) T cell infiltration in colorectal cancer.

PubMed 2023/10/18(内容时间) J Transl Med Q1 · IF 9.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

D594A 突变型 CRC 表现出较低的侵袭性和免疫激活表型。ATF3-THBS1-CXCL9/CXCL10 轴介导功能性 CD8+ T 细胞浸润至 D594A 突变型 CRC 的微环境中。本研究有助于明确该突变在 CRC 中的定义,并为临床设计有效的免疫治疗策略提供重要见解。

研究思路结论见上方概要

BRAF非V600突变在结直肠癌(CRC)中占相对较小但关键的亚群。然而,关于BRAF III类突变在CRC中的生物学功能及影响知之甚少。在此,我们旨在探索D594A突变如何影响小鼠CRC细胞的生物学行为和免疫相关特征。

基于MC38细胞建立了BRAF V600E(I类)、G469V(II类)和D594A(III类)突变细胞系。通过集落形成实验、CCK-8实验、Annexin V/PI染色和transwell实验,从细胞生长、细胞增殖、细胞凋亡、细胞迁移和侵袭方面评估细胞的生物学行为。通过ELISA检测可溶性细胞因子的浓度。通过流式细胞术评估免疫调节分子的膜表达和TIL(肿瘤浸润淋巴细胞)模式。通过RNA测序探索分子机制。采用免疫组织化学(IHC)染色检测肿瘤组织中的CD8α。进行qRT-PCR和western blot以评估mRNA和蛋白表达。在体内模型中进行抗PD-L1治疗和细胞因子中和实验。

D594A突变细胞比V600E(I类)和G469V(II类)突变细胞表现出更低级别的恶性特征。同时,D594A突变导致明显的免疫调节特征,包括MHC I类和PD-L1的上调。体内实验显示,D594A突变肿瘤内浸润性CD8+ T细胞的频率显著较高,这可能为抗PD-L1治疗提供潜在应答。RNA测序分析表明,D594A突变导致ATF3和THBS1表达增强,从而在IFN-γ处理后促进CXCL9和CXCL10的产生。此外,CXCL9或CXCL10中和减少了CD8+ T细胞向过表达THBS1肿瘤的浸润。

展开英文摘要原文

BRAF non-V600 mutation occupies a relatively small but critical subset in colorectal cancer (CRC). However, little is known about the biological functions and impacts of BRAF class III mutation in CRC. Here, we aim to explore how D594A mutation impacts on biological behaviors and immune related signatures in murine CRC cells.

BRAF V600E (class I), G469V (class II) and D594A (class III) mutant cell lines were established based on MC38 cells. The biological behaviors of cells were evaluated in respect of cell growth, cell proliferation, cell apoptosis, cell migration and invasion by the methods of colony-forming assay, CCK-8 assay, Annexin V/PI staining and transwell assay. The concentrations of soluble cytokines were detected by ELISA. The membrane expression of immuno-modulatory molecules and the pattern of tumor infiltrating lymphocyte were evaluated by flow cytometry. The molecular mechanism was explored by RNA sequencing. Immunohistochemistry (IHC) staining was used for the detection of CD8α in tumor tissues. qRT-PCR and western blot were performed to assess the mRNA and protein expression. Anti-PD-L1 treatment and cytokines neutralization experiments were conducted in in vivo models.

D594A mutant cells displayed lower grade malignancy characteristics than V600E (class I) and G469V (class II) mutant cells. Meanwhile, D594A mutation led to evident immuno-modulatory features including upregulation of MHC Class I and PD-L1. In vivo experiments displayed that the frequency of infiltrated CD8 + T cells was significantly high within D594A mutant tumors, which may provide potential response to anti-PD-L1 therapy. RNA sequencing analysis showed that D594A mutation led to enhanced expression of ATF3 and THBS1, which thus facilitated CXCL9 and CXCL10 production upon IFN-γ treatment. In addition, CXCL9 or CXCL10 neutralization reduced the infiltration of CD8 + T cells into THBS1-overexpressing tumors.

D594A mutant CRC exhibited lower aggressiveness and immune-activated phenotype. ATF3-THBS1-CXCL9/CXCL10 axis mediated functional CD8 + T cells infiltration into the microenvironment of D594A mutant CRC. Our present study is helpful to define this mutation in CRC and provide important insights in designing effective immunotherapeutic strategies in clinic.

论文信息

作者
Li W、Zhao C、Li W、Gong Y、Ma K、Lu Y、Liu X、Zhang L
第一作者单位
Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, 215168, Jiangsu, China.China
通讯作者单位
Department of Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, 215001, Jiangsu, China. guofeng27@gmail.com.China
文献类型
非美国政府资助研究
期刊
Journal of translational medicine2023 Oct 18
原文标识
PubMed 37853469 · DOI 10.1186/s12967-023-04606-5